The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients ...

The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

A new mental health and substance abuse treatment facility in Chambers County, Alabama faces opposition from the Birmingham-based Bradford Behavioral Health - a leading substance use disorder ("SUD") ...

Inspired Home Show, the world's leading home and housewares show, returns to Chicago March 2-4, 2025. Intromark, InventHelp's sister licensing company, will again be among exhibitors at this year's ...

Insulin aspart was the second rapidly acting analogue introduced, approved for clinical use in Europe in 1999 and by the FDA in 2000 for patients with Type 1 or Type 2 diabetes. It is obtained by ...

28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill cartridge Novolog Mix 70/30 pen fill cartridge (Novo Nordisk ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.